The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Mechanisms of resistance to venetoclax in AML and methods being explored to overcome these
In this video, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York, NY, discusses mechanisms of resistance to venetoclax in patients with acute myeloid leukemia (AML) and methods being investigated to overcome these. Prof. Konopleva first explains two major mechanisms that have been shown to cause venetoclax resistance, including mutations in signaling pathways and mutations in the TP53 gene, and then goes on to discuss clinical trials evaluating combination approaches to overcome these mechanisms of resistance. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
